Investigational drug · Phase 2
BS006
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Tumor.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "BS006"
First trial start
2023
Sep 7, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BS006", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumor
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "BS006" as an intervention, largest first.
Binhui Biopharmaceutical Co., Ltd.Industry
NCT07382531 · 30 participants (planned) · Start Sep 7, 2023 · Primary completion Dec 31, 2027
Drug: OH2+BS006 · For: Solid Tumor
Sites: Wuhan, China
Binhui Biopharmaceutical Co., Ltd.Industry
NCT05938296 · 29 participants (planned) · Start Dec 19, 2023 · Primary completion Dec 19, 2026
Drug: BS006 Injection · For: Solid Tumor
Sites: Orlando, Florida; Detroit, Michigan
Zhongnan HospitalAcademic, hospital or other
NCT05393440 · 18 participants (planned) · Start Sep 16, 2022 · Primary completion Dec 31, 2023
Drug: BS-006 · For: Uterine Cervical Neoplasms
Sites: Wuhan, China
Newest research
PubMed records naming it or its code names, newest first.
- Effects of Fengycins and Iturins on Fusarium oxysporum f. sp. physali and Root Colonization by Bacillus velezensis Bs006 Protect Golden Berry Against Vascular Wilt.
Moreno-Velandia CA, Ongena M, Cotes AM · Phytopathology 2021
- Biosynthesis of Cyclic Lipopeptides by Bacillus velezensis Bs006 and its Antagonistic Activity are Modulated by the Temperature and Culture Media Conditions.
Moreno-Velandia CA, Ongena M, Kloepper JW, et al. · Curr Microbiol 2021
- Complementary Dynamics of Banana Root Colonization by the Plant Growth-Promoting Rhizobacteria Bacillus amyloliquefaciens Bs006 and Pseudomonas palleroniana Ps006 at Spatial and Temporal Scales.
Gamez RM, Ramirez S, Montes M, et al. · Microb Ecol 2020
- Trichoderma virens Gl006 and Bacillus velezensis Bs006: a compatible interaction controlling Fusarium wilt of cape gooseberry.
Izquierdo-García LF, González-Almario A, Cotes AM, et al. · Sci Rep 2020
- Banana (Musa acuminata) transcriptome profiling in response to rhizobacteria: Bacillus amyloliquefaciens Bs006 and Pseudomonas fluorescens Ps006.
Gamez RM, Rodríguez F, Vidal NM, et al. · BMC Genomics 2019
- Screening, plant growth promotion and root colonization pattern of two rhizobacteria (Pseudomonas fluorescens Ps006 and Bacillus amyloliquefaciens Bs006) on banana cv. Williams (Musa acuminata Colla).
Gamez R, Cardinale M, Montes M, et al. · Microbiol Res 2019
Also in development for Solid Tumor
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.